Truncated isoforms of BRCA1-associated protein BARD1 are expressed in NSCLC and are potential targets for treatment

I. Irminger-Finger, L. Li, F. Molica, J. C. Pache, G. Laurent, A. Bianco (Geneva, Switzerland; London, United Kingdom; Campobasso, Italy)

Source: Annual Congress 2009 - Basic science and lung cancer
Session: Basic science and lung cancer
Session type: Oral Presentation
Number: 3075
Disease area: Thoracic oncology

Congress or journal article abstractSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
I. Irminger-Finger, L. Li, F. Molica, J. C. Pache, G. Laurent, A. Bianco (Geneva, Switzerland; London, United Kingdom; Campobasso, Italy). Truncated isoforms of BRCA1-associated protein BARD1 are expressed in NSCLC and are potential targets for treatment. Eur Respir J 2009; 34: Suppl. 53, 3075

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Oral presentation: Truncated isoforms of BRCA1-associated protein BARD1 are expressed in NSCLC and are potential targets for treatment
Source: Lung Science Conference 2009 - Cell proliferation, Differentiation and Carcinogenesis
Year: 2009



Distinct BARD1 isoforms expressed in lung cancer potential targets for treatment
Source: Annual Congress 2008 - Novel targets in the molecular pathology of lung cancer and COPD
Year: 2008

Nuclear expression of Y-Box binding protein (YB-1) as a negative prognostic marker in non-small cell lung cancer
Source: Annual Congress 2003 - Lung cancer biology
Year: 2003


Cancer-associated oncogenic BARD1 isoforms: From biomarker expression studies to development of a blood test for early detection of lung cancer
Source: Annual Congress 2012 - Early detection of lung cancer
Year: 2012

The prognostic value of altered pRb and p53 protein expression in non-small cell lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 363s
Year: 2003

MDM2 gene amplification and mdm2 protein expression in NSCLC cells
Source: Eur Respir J 2005; 26: Suppl. 49, 91s
Year: 2005

Polymorphisms A1026G and G369C of CDKN1A/p21 and p53 genes in lung cancer
Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics
Year: 2011

Overexpression of inhibitor of DNA-binding proteins and angiogenic markers have higher impact on survival of non small cell lung cancer patients
Source: Annual Congress 2012 - New insights in the pathology of lung cancer
Year: 2012


A new KIF5BERBB4 gene fusion in a lung adenocarcinoma patient
Source: ERJ Open Res, 7 (1) 00582-2020; 10.1183/23120541.00582-2020
Year: 2021



Distinct forms of BARD1 expressed in lung fibrosis and lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 325s
Year: 2006

Activation of NRF2 is responsible for the overexpression of peroxiredoxin and sulphiredoxin in human lung cancer
Source: Annual Congress 2009 - Biological and clinical markers in lung cancer
Year: 2009

Expression of survivin and p53 protein in pulmonary tumours
Source: Annual Congress 2011 - Progress in pathology of lung cancer
Year: 2011

p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance
Source: Eur Respir J 2001; 18: Suppl. 33, 230s
Year: 2001

RNA-binding protein HuR inhibits the expression of sirtuin-1 in patients with COPD
Source: International Congress 2017 – New Mechanistic Findings in COPD
Year: 2017



Prognostic significance and correlation between Akt phosphorylation and loss of PTEN protein expression in non-small cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 458s
Year: 2005

Arg72Pro P53 gene polymorphism is associated with P53 mutations in non-small cell lung cancer (NSCLC) patients
Source: Eur Respir J 2004; 24: Suppl. 48, 78s
Year: 2004

Radiation/cisplatin/vinorelbine therapy increase p53 protein phosphorylated at serine 392 in recurrent primary squamous cell lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 17s
Year: 2001

Polymorphism in GSTM1, GSTT1, p53 and CCR5 genes and lung cancer progression: relation to p53 and Ki-67 protein expression in tumors of non-small cell lung cancer patients
Source: Eur Respir J 2006; 28: Suppl. 50, 810s
Year: 2006

p53 gene mutations in lung cancer in Korean
Source: Eur Respir J 2005; 26: Suppl. 49, 327s
Year: 2005

N-terminal deletion augments the cell death-inducing activity of BAX in the adenoviral gene delivery to nonsmall cell lung cancers
Source: Eur Respir J 2002; 20: Suppl. 38, 14s
Year: 2002